Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027

Beam Therapeutics Inc.

2024-Q1 EPS reported -$1.21 revenue$7,410,000

Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.
Cash, cash equivalents and marketable securities $1.1B as of March 31, 2024; runway into 2027.
R&D expenses $84.8M, G&A expenses $26.7M for Q1 2024.
BEAM-101 BEACON trial sentinel cohort dosing completed; expansion cohort initiated with up to 45 patients.
BEAM-302 CTA cleared in UK for Phase 1/2 in AATD; BEAM-301 IND submission on track for H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported first quarter 2024 results: net income ($98.7 million), EPS ($1.21).

Period: first quarter 2024
Net income: ($98.7 million)
EPS: ($1.21)
Result: reported results

Exact text from the filing

Net loss was $98.7 million for the first quarter of 2024, or $1.21 per share, compared to $96.5 million for the first quarter of 2023, or $1.33 per share.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053928

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.